<DOC>
	<DOC>NCT00950807</DOC>
	<brief_summary>The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.</brief_summary>
	<brief_title>GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This is multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-way cross-over, incomplete block design study to evaluation of 5 doses of GSK573719 administered once-daily and 3 doses of GSK573719 administered twice-daily over 14 days in subjects with COPD and will include tiotropium as an open-label active control. The pharmacokinetic profile of GSK573719 will also be evaluated.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>A signed and dated written informed consent prior to study participation Males or females of nonchildbearing potential 40 to 80 years of age COPD diagnosis 10 packyears history or greater of cigarette smoking Postbronchodilator FEV1/FVC ratio of 0.70 or less Postbronchodilator FEV1 of 35 to 70% of predicted normal Asthma Other significant respiratory disorders besides COPD, including alpha1 deficiency Previous lung resection surgery Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of screening Hospitalization for COPD or pneumonia within 3 months of screening Any significant disease that would put subject at risk through study participation BMI greater than 35 Pacemaker Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or C) Cancer Allergy or hypersensitivity to anticholinergics or inhaler excipients Diseases that would contraindicate the use of anticholinergics Use of oral corticosteroids within 6 weeks of screening Use of longacting betaagonists within 48 hours of screening Use of tiotropium within 14 days of screening Use of theophyllines or antileukotrienes within 48 hours of screening Use of shortacting bronchodilators within 4 to 6 hours of screening Use of investigational medicines within 30 days of screening Use of high dose inhaled corticosteroids Use of longterm oxygen therapy, CPAP or NIPPV Previous use of GSK573719</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dose ranging</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Long-acting muscarinic antagonist</keyword>
	<keyword>cross-over</keyword>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>anticholinergic</keyword>
</DOC>